IGC Pharma (IGC) Stock Price, News & Analysis

Company Overview

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Key Stats

• Today's Range: $0.32 to $0.34
• 50-Day Range: $0.29 to $0.40
• 52-Week Range: N/A
• Volume: 214,616 shs
• Average Volume: 386,489 shs
• Market Capitalization: $23.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

IGC Pharma Stock Analysis - MarketRank™

IGC Pharma scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

IGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IGC Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for IGC Pharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IGC Pharma is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGC Pharma is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGC Pharma has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IGC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGC Pharma does not currently pay a dividend.

Dividend Growth

IGC Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IGC.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.13

News Sentiment

IGC Pharma has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for IGC Pharma this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for IGC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IGC Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.48% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.87% of the stock of IGC Pharma is held by institutions.

IGC Stock Analysis - Frequently Asked Questions

How have IGC shares performed this year?

IGC Pharma's stock was trading at $0.3360 on January 1st, 2025. Since then, IGC stock has decreased by 11.6% and is now trading at $0.2970.
View the best growth stocks for 2025 here.

How were IGC Pharma's earnings last quarter?

IGC Pharma, Inc. (NYSEMKT:IGC) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business earned $0.41 million during the quarter, compared to the consensus estimate of $0.29 million. IGC Pharma had a negative net margin of 714.16% and a negative trailing twelve-month return on equity of 122.44%.

Who are IGC Pharma's major shareholders?

IGC Pharma's top institutional investors include Geode Capital Management LLC (0.86%), Squarepoint Ops LLC (0.16%), Northern Trust Corp (0.15%) and Citadel Advisors LLC.
View institutional ownership trends.

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include Jiuzi (JZXN), Plug Power (PLUG), Avalon GloboCare (ALBT), Ainos (AIMD), Aethlon Medical (AEMD), Aditxt (ADTX) and Adial Pharmaceuticals (ADIL).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/21/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEMKT
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEMKT:IGC
• CUSIP: N/A
• CIK: 1326205
• Web: igcpharma.com
• Phone: (301) 983-0998
• Fax: 240-465-0273
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +1,246.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,000,000.00
• Net Margins: -714.16%
• Pretax Margin: -712.70%
• Return on Equity: -122.44%
• Return on Assets: -88.40%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 1.15
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $1.35 million
• Price / Sales: 17.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 3.71

Miscellaneous

• Outstanding Shares: 79,680,000
• Free Float: 54,600,000
• Market Cap: $23.66 million
• Optionable: N/A
• Beta: 1.32